Oncoc4 announces first patient with advanced prostate cancer dosed in phase 1/2 trial of biontech-partnered bnt316/onc-392 program

Rockville, md., feb. 22, 2024 (globe newswire) -- oncoc4, inc. (“oncoc4”) today announced that the first patient with metastatic castration resistant prostate cancer (“mcrpc”) has been dosed in a phase 1/2 trial evaluating the anti-ctla-4 antibody candidate bnt316/onc-392 (gotistobart) in combination with radioligand therapy, lutetium (177lu) vipivotide tetraxetan (pluvicto®). bnt316/onc-392 is being jointly developed by biontech and oncoc4.
BNTX Ratings Summary
BNTX Quant Ranking